B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with stubborn leukemia: cell therapy targets remaining cancer
Disease control OngoingThis study tests a one-time cell therapy (tisagenlecleucel) in children and young adults aged 1 to 25 with high-risk B-cell acute lymphoblastic leukemia who still have small amounts of cancer after initial chemotherapy. The goal is to see if the treatment can keep the cancer away…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
Double-Dose CAR t strategy aims to outsmart relapsed leukemia in kids
Disease control OngoingThis study tests whether giving a second, early infusion of the CAR T-cell therapy tisagenlecleucel can keep B-cell aplasia (a sign the treatment is working) going for at least 6 months in children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemi…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New combo therapy shows promise for hard-to-treat leukemia
Disease control OngoingThis early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL). About 23 adults with CD22-positive B-ALL that has come back or not responded to treatment will receiv…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Experimental 'Natural Killer' cell therapy takes on tough blood cancers
Disease control OngoingThis early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…
Matched conditions: B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC